Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Rveiling + Lidocaine is a cross-linked hyaluronic acid dermal filler combined with 0.3% lidocaine hydrochloride, developed by Aowita Biotech. The product utilizes a patented cross-linking technology involving natural entanglement of high molecular weight hyaluronic acid and chemical modification with BDDE to create a stable, three-dimensional gel matrix. This structure resists enzymatic degradation, providing long-lasting volume for tissue augmentation, structural support, and aesthetic contouring. The inclusion of lidocaine serves as a local anesthetic to reduce pain and discomfort during the injection process. It is indicated for deep subcutaneous or superficial periosteal injection for applications such as buttock augmentation, facial volumization, and hand rejuvenation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on hyaluronic acid + lidocaine (Aowita).